Cat. No. 0892
Chemical Name: 17-(Cyclopropylmethyl)-6,7-didehydr
Biological ActivitySelective and potent δ-opioid receptor antagonist (Ki values are 0.013, 19 and 152 nM for δ, μ and κ receptors respectively). Displays selectivity for the δ2 subtype in vivo.
Licensing InformationSold with the permission of the University of Minnesota
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Datasheet
References are publications that support the products' biological activity.
Thorat and Hammond (1997) Modulation of nociception by microinjection of delta-1 and delta-2 opioid receptor ligands in the ventromedial medulla of the rat. J.Pharmacol.Exp.Ther. 283 1185. PMID: 9399992.
Miyamoto et al (1993) Involvement of delta2 opioid receptors in the development of morphine dependence in mice. J.Pharmacol.Exp.Ther. 264 1141. PMID: 8383738.
Portoghese et al (1991) Role of spacer and address components in peptidomimetic δ opioid receptor antagonists related to naltrindole. J.Med.Chem. 34 1715. PMID: 1851846.
If you know of a relevant reference for Naltriben mesylate please let us know.
Citations are publications that use Tocris products. Selected citations for Naltriben mesylate include:
Gomes et al (2000) Heterodimerization of μ and δ opioid receptors: A role in opiate synergy. Exp Neurobiol 20 RC110. PMID: 11069979.
Do you know of a great paper that uses Naltriben mesylate from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: Naltriben mesylate, supplier, δ2-opioid, delta2-opioid, selective, antagonists, DOP, Receptors, OP1, Tocris Bioscience, δ Opioid Receptor Antagonist products
Find multiple products by catalog number
New Products in this Area
Fluorescent opioid antagonist; fluorescent-derivative of naloxone (Cat. No. 0599)
Follow Tocris on LinkedIn
Visit our LinkedIn page for the latest Tocris news, events and updates.